M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Malaria Infection
Conditions
Malaria Infection
Trial Timeline
Nov 28, 2023 → Dec 29, 2024
NCT ID
NCT05974267About M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mg
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mg is a phase 2 stage product being developed by Merck for Malaria Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05974267. Target conditions include Malaria Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05974267 | Phase 2 | Completed |
Competing Products
20 competing products in Malaria Infection